These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. Belfort R; Berria R; Cornell J; Cusi K J Clin Endocrinol Metab; 2010 Feb; 95(2):829-36. PubMed ID: 20061429 [TBL] [Abstract][Full Text] [Related]
6. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats. Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065 [TBL] [Abstract][Full Text] [Related]
8. Fenofibrate lowers lipid accumulation in myotubes by modulating the PPARα/AMPK/FoxO1/ATGL pathway. Chen WL; Chen YL; Chiang YM; Wang SG; Lee HM Biochem Pharmacol; 2012 Aug; 84(4):522-31. PubMed ID: 22687626 [TBL] [Abstract][Full Text] [Related]
9. Hepatic Lee YH; Jang HJ; Kim S; Choi SS; Khim KW; Eom HJ; Hyun J; Shin KJ; Chae YC; Kim H; Park J; Park NH; Woo CY; Hong CH; Koh EH; Nam D; Choi JH Elife; 2021 Dec; 10():. PubMed ID: 34964438 [TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect. Yan F; Wang Q; Xu C; Cao M; Zhou X; Wang T; Yu C; Jing F; Chen W; Gao L; Zhao J PLoS One; 2014; 9(6):e99245. PubMed ID: 24926685 [TBL] [Abstract][Full Text] [Related]
11. Fenofibrate prevents obesity and hypertriglyceridemia in low-density lipoprotein receptor-null mice. Jeong S; Kim M; Han M; Lee H; Ahn J; Kim M; Song YH; Shin C; Nam KH; Kim TW; Oh GT; Yoon M Metabolism; 2004 May; 53(5):607-13. PubMed ID: 15131765 [TBL] [Abstract][Full Text] [Related]
13. Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy. Yoo J; Jeong IK; Ahn KJ; Chung HY; Hwang YC Metabolism; 2021 Jul; 120():154798. PubMed ID: 33984335 [TBL] [Abstract][Full Text] [Related]
14. Activation of peroxisome proliferator-activated receptor-alpha in mice induces expression of the hepatic low-density lipoprotein receptor. Huang Z; Zhou X; Nicholson AC; Gotto AM; Hajjar DP; Han J Br J Pharmacol; 2008 Oct; 155(4):596-605. PubMed ID: 18852694 [TBL] [Abstract][Full Text] [Related]
15. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells. Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265 [TBL] [Abstract][Full Text] [Related]
16. Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. Jeong S; Han M; Lee H; Kim M; Kim J; Nicol CJ; Kim BH; Choi JH; Nam KH; Oh GT; Yoon M Metabolism; 2004 Oct; 53(10):1284-9. PubMed ID: 15375783 [TBL] [Abstract][Full Text] [Related]
17. Fish oil and fenofibrate prevented phosphorylation-dependent hepatic sortilin 1 degradation in Western diet-fed mice. Li J; Bi L; Hulke M; Li T J Biol Chem; 2014 Aug; 289(32):22437-49. PubMed ID: 24986865 [TBL] [Abstract][Full Text] [Related]
18. Kaempferol regulates the lipid-profile in high-fat diet-fed rats through an increase in hepatic PPARα levels. Chang CJ; Tzeng TF; Liou SS; Chang YS; Liu IM Planta Med; 2011 Nov; 77(17):1876-82. PubMed ID: 21728151 [TBL] [Abstract][Full Text] [Related]
19. The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-α agonist-induced amelioration of metabolic disorders in obese mice. Goto T; Hirata M; Aoki Y; Iwase M; Takahashi H; Kim M; Li Y; Jheng HF; Nomura W; Takahashi N; Kim CS; Yu R; Seno S; Matsuda H; Aizawa-Abe M; Ebihara K; Itoh N; Kawada T J Biol Chem; 2017 Jun; 292(22):9175-9190. PubMed ID: 28404815 [TBL] [Abstract][Full Text] [Related]